Intellia Therapeutics vs Alpha Teknova
NTLA and TKNO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NTLA and TKNO compare
Intellia Therapeutics is the larger company, worth 3.5 times as much as Alpha Teknova ($1.6B against $463M).
Alpha Teknova grew revenue faster over the last twelve months (15.4% versus −8.1% for Intellia Therapeutics).
Alpha Teknova keeps more of each dollar of sales as profit, with a net margin of −34.8% compared with −806% at Intellia Therapeutics.
Alpha Teknova scores higher on the StockData Score (12 against 3 for Intellia Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NTLA | TKNO |
|---|---|---|
| Size and price | ||
| Market cap | $1.6B | $463M |
| Share price | $11.41 | $8.62 |
| Change, 1 year | 17.3% | 87.0% |
| Change, 5 years | −91.2% | −65.5% |
| Beta (5Y) | 2.11 | 1.19 |
| Employees | 377 | 158 |
| StockData Score | ||
| Total score | 3 | 12 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 3 (better) |
| Performance score | 1 | 3 (better) |
| Health score | 2 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 30.2× | 10.1× (better) |
| P/B | 2.6× (better) | 7.7× |
| FCF yield | −22.4% | −1.4% (better) |
| Fair value | $7.99 | $3.45 |
| Margin of safety | −42.8% (better) | −150% |
| Growth | ||
| Revenue growth (TTM) | −8.1% | 15.4% (better) |
| Revenue growth, 5Y average | 3.1% | 5.3% (better) |
| Profitability | ||
| Gross margin | – | 36.4% |
| Operating margin | −821% | −32.7% (better) |
| Net margin | −806% | −34.8% (better) |
| FCF margin | −677% | −13.9% (better) |
| Return on equity | −62.6% | −24.1% (better) |
| Return on invested capital | −152% | −25.3% (better) |
| Financial health | ||
| Debt / equity | 0.12 (better) | 0.00 |
| Current ratio | 6.31 (better) | 3.56 |
| Altman Z-score | −2.18 | 6.03 (better) |
| Piotroski F-score | 3 | 6 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 103% | 17.0% |
| Held by insiders | 2.0% | 1.3% |
| Insider net buying, 12 months | −$869K | $144K (better) |
| Short interest, % of float | 32.3% | 2.9% |
Go deeper
- NTLA stock overview
- NTLA income statement
- NTLA valuation and score
- TKNO stock overview
- TKNO income statement
- TKNO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.